433 studies found for:    Wilson Disease
Show Display Options
Rank Status Study
1 Completed
Has Results
Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease
Condition: Wilson Disease
Intervention: Drug: Once a day Trientine
2 Completed Study of Zinc for Wilson Disease
Condition: Wilson Disease
Intervention: Drug: zinc acetate
3 Completed
Has Results
Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.
Condition: Wilson's Disease
Intervention: Drug: NPC-02
4 Completed A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients
Condition: Wilson's Disease
Intervention: Drug: trientine dihydrochloride
5 Completed Study of Tetrathiomolybdate in Patients With Wilson Disease
Condition: Wilson Disease
Interventions: Drug: tetrathiomolybdate;   Drug: trientine
6 Recruiting Inhibitory rTMS in Dystonic Wilson Patients
Conditions: Wilson Disease;   Movement Disorders;   Repetitive Transcranial Magnetic Stimulation
Interventions: Device: Repetitive Transcranial Magnetic Stimulation (rTMS);   Other: pre and post-rTMS electroencephalogram;   Other: WCRS;   Other: handwriting scale DPRE;   Other: visual analog scale of discomfort writing and parameters collected on touchpad
7 Completed Efficacy and Safety Study of Zinc Acetate to Treat Wilson's Disease in Japan.
Condition: Wison's Disease
Intervention: Drug: Zinc acetate
8 Unknown  Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis
Condition: Wilson's Disease
Intervention: Genetic: allogeneic mesenchymal stem cell transplantation
9 Recruiting Evaluation of Patients With Liver Disease
Conditions: Biliary Liver Cirrhosis,;   Hemochromatosis;   Hepatitis;   Hepatolenticular Degeneration;   Liver Disease
Intervention:
10 Not yet recruiting ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
Conditions: Movement Disorders;   Essential Tremor;   Holmes Tremor;   Parkinson's Disease;   Wilson's Disease;   Huntington's Disease;   Dystonia;   Tardive Dyskinesia;   Orofacial Dyskinesias
Intervention: Device: Transcranial ExAblate System
11 Unknown  Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome (SIRS), Sepsis or Chronicle Liver Disease on Intensive Care Units (ICU)
Conditions: SIRS;   Sepsis;   Liver Disease
Intervention:
12 Completed A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris
Condition: Psoriasis
Intervention: Drug: Tetrathiomolybdate (TM)
13 Recruiting A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
Condition: Melanoma
Intervention: Drug: Vemurafenib and Trientine
14 Completed Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver
Condition: Cancer
Interventions: Drug: Disulfiram;   Drug: Copper Gluconate
15 Completed Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)
Conditions: Fatty Liver Disease.;   Endoscopic Ultrasound Tru-Cut Biopsy.
Intervention: Device: EUS Tru-cut biopsy
16 Unknown  Interstitial Lung Disease Questionnaire
Condition: Interstitial Lung Disease
Intervention:
17 Recruiting Study and Treatment of Inflammatory Muscle Diseases
Conditions: Autoimmune Disease;   Dermatomyositis;   Inclusion Body Myositis;   Myositis;   Polymyositis
Intervention:
18 Active, not recruiting Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)
Condition: Hyperphosphatemia
Intervention:
19 Terminated
Has Results
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Drug: thalidomide;   Radiation: radiation therapy
20 Completed
Has Results
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
Condition: Alzheimer's Disease
Interventions: Drug: Rivastigmine 4.6 mg/24 h (5 cm^2);   Drug: Rivastigmine 9.5 mg/24 h (10 cm^2);   Drug: Rivastigmine 13.3 mg/24 h (15 cm^2);   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years